Therapy News and Research

RSS

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

START proteins could help treat cholesterol build-up in arteries: Report

A newly discovered group of proteins could help treat cholesterol build-up in arteries. This build-up leads to atherosclerosis or 'hardening of the arteries', and the resulting condition, coronary heart disease, kills an estimated 124,000 each year in England and Wales.

23 Jun 2010

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

Spanish scientists have proposed using human amniotic membrane as a new tool for repairing damaged human articular cartilage, which heals very poorly because of its low capacity for self-repair. Their research, published in the journal Cell and Tissue Banking, shows that the cellular density of the cartilage synthesised could be greater than that of the body's own natural cartilage.

23 Jun 2010

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Groundbreaking studies will be presented at the ESMO 12th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. "The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases," says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven, Belgium and Congress co-chair.

23 Jun 2010

imec researchers demonstrate biosensors that detect extremely low concentrations of disease markers

Researchers at the nanotechnology research centre imec have demonstrated biosensors based on novel nanostructure geometries that increase the sensitivity and allow to detect extremely low concentrations of specific disease markers. This paves the way to early diagnostics of for example cancer by detecting low densities of cancer markers in human blood samples.

23 Jun 2010

Infusion Nurses Society paper states role of RNs in using IO access devices

The American Association of Critical-Care Nurses recently endorsed "The Role of the Registered Nurse in the Insertion of Intraosseous Access Devices," an official position paper from the Infusion Nurses Society, Norwood, Mass.

23 Jun 2010

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Misperceptions about 'light,' 'low,' 'mild' cigarettes

Today, new legislation will go into effect surrounding the ban of word descriptors such as "light," "low," and "mild" on all packaging and advertising of existing cigarettes and smokeless products. However, a new survey, sponsored by GlaxoSmithKline (GSK) Consumer Healthcare, shows that many smokers will choose the cigarettes in lighter-colored packaging because they incorrectly believe these cigarettes would be less harmful to their health or make it easier to quit smoking.

23 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

Karolinska Institutet receives SEK 100M grant for Wallenberg Institute for Regenerative Medicine

Karolinska Institutet has received a grant of SEK 100 million from the Knut and Alice Wallenberg Foundation for a regenerative medicine research centre - the Wallenberg Institute for Regenerative Medicine (WIRM). This funding will give Karolinska Institutet a unique opportunity to concentrate on new and pioneering research, with a special focus on the blood system.

23 Jun 2010

Researchers identify promising gene therapy for DMD

CureDuchenne, the Orange County non-profit focused on finding a cure for Duchenne muscular dystrophy (DMD) is one step closer to that goal through the work of Dr. Jeff Chamberlain.

23 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Walmart and Eli Lilly and Company announced today they're teaming up to provide an affordable insulin option for people with diabetes.

23 Jun 2010

Study investigates benefits of filtering blood to create safer approaches to transfusion therapy

Researchers at the University of Rochester Medical Center have discovered yet another reason to filter the foreign white cells from donor blood: The resulting blood product is associated with dramatically fewer cardiopulmonary complications for patients who received a transfusion.

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Data on Qnexa to be featured in six presentations at ADA annual meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association, being held from June 25-29, 2010 in Orlando, Florida.

22 Jun 2010

Therapy News and Research

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

START proteins could help treat cholesterol build-up in arteries: Report

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

imec researchers demonstrate biosensors that detect extremely low concentrations of disease markers

Infusion Nurses Society paper states role of RNs in using IO access devices

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Misperceptions about 'light,' 'low,' 'mild' cigarettes

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Karolinska Institutet receives SEK 100M grant for Wallenberg Institute for Regenerative Medicine

Researchers identify promising gene therapy for DMD

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Study investigates benefits of filtering blood to create safer approaches to transfusion therapy

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Data on Qnexa to be featured in six presentations at ADA annual meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News